Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Post by Derby44on Dec 12, 2017 12:36pm
310 Views
Post# 27139049

Reply from TBP on Facebook about Dec 9 news

Reply from TBP on Facebook about Dec 9 newsTetra Bio-Pharma Health Canada is asking us to switch 2 steps of the submission process. Usually, the GMP certification is evaluated after the phase 3 clinical trial for a drug. As this this the first cannabis phase 3 trial and the active ingredient (API) is a plant, OCT (Office of Clinical Trials) recognizes they are outside of the regulations. They want to make sure of the quality of our API, so Health Canada will assess Aphria's operations for Good Manufacturing Practices (GMP) for pharmaceutical products before the beginning of the phase 3 instead. As those 2 steps had to take place for the DIN submission anyway, this should not affect our time to market for PPP001. 
This is actually good news because it ensures the quality and safety of our product for patients and a GMP certification should reassure doctors who are reluctant prescribing cannabis.



<< Previous
Bullboard Posts
Next >>